Cargando…

Olanzapine-Induced Hyperprolactinemia: Two Case Reports

Background: Hyperprolactinemia is a common consequence of treatment with antipsychotics. It is usually defined by a sustained prolactin level above the laboratory upper level of normal in conditions other than that where physiologic hyperprolactinemia is expected. Normal prolactin levels vary signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Barata, Pedro Cabral, Santos, Mário João, Melo, João Carlos, Maia, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680598/
https://www.ncbi.nlm.nih.gov/pubmed/31417404
http://dx.doi.org/10.3389/fphar.2019.00846
_version_ 1783441537208680448
author Barata, Pedro Cabral
Santos, Mário João
Melo, João Carlos
Maia, Teresa
author_facet Barata, Pedro Cabral
Santos, Mário João
Melo, João Carlos
Maia, Teresa
author_sort Barata, Pedro Cabral
collection PubMed
description Background: Hyperprolactinemia is a common consequence of treatment with antipsychotics. It is usually defined by a sustained prolactin level above the laboratory upper level of normal in conditions other than that where physiologic hyperprolactinemia is expected. Normal prolactin levels vary significantly among different laboratories and studies. Several studies indicate that olanzapine does not significantly affect serum prolactin levels in the long term, although this statement has been challenged. Aims: Our aim is to report two olanzapine-induced hyperprolactinemia cases observed in psychiatric consultations. Methods: Medical records of the patients who developed this clinical situation observed in psychiatric consultations in the Psychiatry Department of the Prof. Dr. Fernando Fonseca Hospital during the year of 2017 were analyzed, complemented with a non-systematic review of the literature. Results: The case reports consider two women who developed prolactin-related symptoms after the initiation of olanzapine. No baseline prolactinemia was obtained, and prolactin serum levels were only evaluated after prolactin-related symptoms developed: at the time of its measurement, both patients had been taking olanzapine for more than 24 weeks. Hyperprolactinemia was found to be present in Case 2, whereas Case 1 (a 49-year-old woman) had “normal” serum prolactin levels for premenopausal and prolactin levels slightly above the maximum levels for postmenopausal women. Both patients underwent similar pharmacological adjustments, which comprised switches from olanzapine to aripiprazole. After all pharmacological changes, prolactin serum levels decreased to normal range values and prolactin-related symptoms disappeared. Discussion/Conclusions: Laboratorial and literature prolactinemia values variability and discrepancies may make the management of borderline hyperprolactinemia clinical situations difficult. Baseline prolactin levels should have been obtained, as they help in the management of patients who develop neuroleptic-induced hyperprolactinemia. Prolactin-related symptoms can occur with borderline or normal standardized prolactinemia values. Olanzapine-induced hyperprolactinemia is a rare but possible event. Aripiprazole was used as a suitable alternative for olanzapine-induced hyperprolactinemia.
format Online
Article
Text
id pubmed-6680598
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66805982019-08-15 Olanzapine-Induced Hyperprolactinemia: Two Case Reports Barata, Pedro Cabral Santos, Mário João Melo, João Carlos Maia, Teresa Front Pharmacol Pharmacology Background: Hyperprolactinemia is a common consequence of treatment with antipsychotics. It is usually defined by a sustained prolactin level above the laboratory upper level of normal in conditions other than that where physiologic hyperprolactinemia is expected. Normal prolactin levels vary significantly among different laboratories and studies. Several studies indicate that olanzapine does not significantly affect serum prolactin levels in the long term, although this statement has been challenged. Aims: Our aim is to report two olanzapine-induced hyperprolactinemia cases observed in psychiatric consultations. Methods: Medical records of the patients who developed this clinical situation observed in psychiatric consultations in the Psychiatry Department of the Prof. Dr. Fernando Fonseca Hospital during the year of 2017 were analyzed, complemented with a non-systematic review of the literature. Results: The case reports consider two women who developed prolactin-related symptoms after the initiation of olanzapine. No baseline prolactinemia was obtained, and prolactin serum levels were only evaluated after prolactin-related symptoms developed: at the time of its measurement, both patients had been taking olanzapine for more than 24 weeks. Hyperprolactinemia was found to be present in Case 2, whereas Case 1 (a 49-year-old woman) had “normal” serum prolactin levels for premenopausal and prolactin levels slightly above the maximum levels for postmenopausal women. Both patients underwent similar pharmacological adjustments, which comprised switches from olanzapine to aripiprazole. After all pharmacological changes, prolactin serum levels decreased to normal range values and prolactin-related symptoms disappeared. Discussion/Conclusions: Laboratorial and literature prolactinemia values variability and discrepancies may make the management of borderline hyperprolactinemia clinical situations difficult. Baseline prolactin levels should have been obtained, as they help in the management of patients who develop neuroleptic-induced hyperprolactinemia. Prolactin-related symptoms can occur with borderline or normal standardized prolactinemia values. Olanzapine-induced hyperprolactinemia is a rare but possible event. Aripiprazole was used as a suitable alternative for olanzapine-induced hyperprolactinemia. Frontiers Media S.A. 2019-07-29 /pmc/articles/PMC6680598/ /pubmed/31417404 http://dx.doi.org/10.3389/fphar.2019.00846 Text en Copyright © 2019 Barata, Santos, Melo and Maia http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Barata, Pedro Cabral
Santos, Mário João
Melo, João Carlos
Maia, Teresa
Olanzapine-Induced Hyperprolactinemia: Two Case Reports
title Olanzapine-Induced Hyperprolactinemia: Two Case Reports
title_full Olanzapine-Induced Hyperprolactinemia: Two Case Reports
title_fullStr Olanzapine-Induced Hyperprolactinemia: Two Case Reports
title_full_unstemmed Olanzapine-Induced Hyperprolactinemia: Two Case Reports
title_short Olanzapine-Induced Hyperprolactinemia: Two Case Reports
title_sort olanzapine-induced hyperprolactinemia: two case reports
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680598/
https://www.ncbi.nlm.nih.gov/pubmed/31417404
http://dx.doi.org/10.3389/fphar.2019.00846
work_keys_str_mv AT baratapedrocabral olanzapineinducedhyperprolactinemiatwocasereports
AT santosmariojoao olanzapineinducedhyperprolactinemiatwocasereports
AT melojoaocarlos olanzapineinducedhyperprolactinemiatwocasereports
AT maiateresa olanzapineinducedhyperprolactinemiatwocasereports